Supplements
Biotin: vitamin functions, foods, deficiency, inherited disorders, hair claims, uncertain benefits and laboratory safety
On this page
Biotin is an essential, water-soluble B vitamin involved in metabolism of fats, glucose and amino acids. Its nutritional role differs from using a high-dose supplement to treat disease or change hair growth.[1]
Separate vitamin status, inherited disease and assay effects
| Category | Meaning | Interpretation boundary |
|---|---|---|
| Biotin as a nutrient | A cofactor for enzymes involved in fat, amino-acid and glucose metabolism | Normal function does not imply benefit from extra intake[2] |
| Free and protein-bound biotin | Forms found in foods; bound biotin requires release before reuse or absorption | A food matrix and an isolated supplement are different exposures[3] |
| Nutritional deficiency | Insufficient available biotin under particular circumstances | Hair changes alone do not establish deficiency[3] |
| Biotinidase deficiency | An inherited disorder affecting release and recycling of biotin | Needs disease-specific confirmation and professional management[4] |
| Assay interference | Supplement biotin can alter some laboratory test results | Different from the person lacking biotin[5] |
Adequate Intake reflects limited requirement evidence
EFSA describes dietary biotin deficiency as rare. Its 2014 opinion found insufficient evidence to derive an average requirement and population reference intake for biotin. Its Adequate Intake used observed mixed-diet intakes and the apparent absence of deficiency signs, with pregnancy and lactation considered separately. Biomarker data were insufficient to determine the requirement. These population references are not tests for an individual deficiency, and an intake below an Adequate Intake does not prove inadequacy. A nutrient requirement is also different from a pharmacological exposure tested for a disease.[2]
Dietary form and uncommon deficiency contexts matter
The US report describes free and protein-bound biotin in foods, with varying concentrations; liver is a rich source. It documents deficiency with prolonged raw egg-white consumption, whose avidin binds biotin, and historically with biotin-free parenteral nutrition. Deficiency can involve skin, hair and neurological changes, but these findings have other causes. They require clinical assessment rather than a cosmetic supplement diagnosis.[3]
An inherited metabolic disorder is not ordinary low dietary intake
The 2026 GeneReviews update explains that biotinidase deficiency requires confirmation through enzyme activity or, when appropriate, genetic testing. Newborn screening can identify affected infants before symptoms appear. Disease-specific biotin treatment is important, and some established hearing, vision or developmental effects may not fully reverse. An abnormal screening result requires prompt follow-up with the clinical team. This disorder should not be inferred from an adult’s cosmetic concern or used to justify a general supplement regimen. Professional management differs from choosing an over-the-counter beauty product.[4]
Laboratory interference is a separate safety problem
FDA warns that supplement biotin can distort certain assays, including falsely low troponin results. Tell the clinical and laboratory team about biotin-containing products. Interference depends on the assay; this guide supplies no universal stopping interval. The dedicated biotin-lab-tests guide explains this issue in greater depth.[5]
Evidence & uncertainty
A 2026 review concluded that current evidence does not support routine biotin supplementation for alopecia without documented deficiency. In combined interventions, improvement cannot automatically be attributed to biotin. This evidence limitation differs from denying the vitamin’s essential metabolic role.[8]
Selected-source overview · Independent review pendingPublished questions
Does an Adequate Intake provide a diagnostic deficiency threshold?
Selected-source overview · Independent review pending. Read the evidence context.
No. EFSA used observed intake because requirement evidence was limited. The population reference cannot diagnose an individual or select a personal supplement dose.[2]
Evidence behind this answer
- Scientific Opinion on Dietary Reference Values for biotin
reference intake report · 2014
Original abstract and bibliographic record inspected on 2026-10-14 UTC; full text not independently appraised · 2014-02-24; Original abstract; functions, rare dietary deficiency, AI and biomarker limits
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can prolonged raw egg-white intake affect biotin availability?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. Avidin binds biotin and can hinder absorption. This unusual deficiency context does not establish that ordinary hair shedding is caused by low biotin.[3]
Evidence behind this answer
- Dietary Reference Intakes: Chapter 11, Biotin
reference intake report · 1998
Selected original official guidance or reference-report passages inspected on 2026-10-14 UTC; no independent clinical appraisal · 1998; Original chapter 11; free/bound forms, food sources, avidin, deficiency and insufficient UL data
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is biotinidase deficiency the same as simply eating too little biotin?
Selected-source overview · Independent review pending. Read the evidence context.
No. It is an inherited metabolic disorder requiring disease-specific confirmation and management. Newborn screening follow-up is important even before symptoms appear.[4]
Evidence behind this answer
- Biotinidase Deficiency
clinical reference · 2026
Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised · 2026-02-19; Last revision; original indexed diagnosis, newborn screening and management summary
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do depletion experiments validate every consumer biotin test?
Selected-source overview · Independent review pending. Read the evidence context.
No. The small controlled study examined specific biochemical indicators during induced depletion. It does not validate routine consumer diagnosis of hair-loss causes.[6]
Evidence behind this answer
- Indicators of marginal biotin deficiency and repletion in humans
controlled depletion experiment · 2002
Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised · 2002-11; Original indexed abstract and selected methods; eleven adults, twenty-eight days, urinary markers
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do the eighteen early cases prove cosmetic benefit in healthy people?
Selected-source overview · Independent review pending. Read the evidence context.
No. They involved underlying pathology and lacked the protection against bias provided by appropriate controlled trials. Their results do not establish routine benefit.[7]
Evidence behind this answer
- A Review of the Use of Biotin for Hair Loss
systematic review · 2017
Original abstract and bibliographic record inspected on 2026-10-14 UTC; full text not independently appraised · 2017-04-27; Original abstract; eighteen reported cases and healthy-population evidence limit
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the newer alopecia review support routine supplementation without deficiency?
Selected-source overview · Independent review pending. Read the evidence context.
No. It found insufficient support for routine use. Improvements during combined regimens cannot automatically be assigned to biotin alone.[8]
Evidence behind this answer
- Effectiveness of Biotin Supplementation for Hair Growth in Patients with Alopecia: A Systematic Review
systematic review · 2026
Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised · 2026-05-04; Original indexed conclusions and selected discussion; routine use, combinations and attribution
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did SPI2 establish that high-dose biotin improves progressive multiple sclerosis?
Selected-source overview · Independent review pending. Read the evidence context.
No. The large placebo-controlled trial did not establish disability or walking-speed improvement. Its findings do not negate treatment of actual biotin deficiency.[9]
Evidence behind this answer
- Safety and efficacy of MD1003 in progressive multiple sclerosis (SPI2): phase 3 trial
randomized controlled trial · 2020
Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised · 2020-12; Journal issue; original indexed abstract, 642 randomized, primary outcome and null interpretation
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can biotin supplements affect a troponin laboratory result?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. FDA reports falsely low results with some assays. Inform the testing team about biotin products; the appropriate approach depends on the assay.[5]
Evidence behind this answer
- Biotin Interference with Troponin Lab Tests: Assays Subject to Biotin Interference
agency condition or prevention explanation · Date not stated
Selected original official guidance or reference-report passages inspected on 2026-10-14 UTC; no independent clinical appraisal · Undated; Current visible warning text; false troponin results and assay-specific mitigation
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
A depletion experiment investigated metabolic indicators
Mock and colleagues’ 2002 study deliberately induced marginal biotin depletion using an egg-white diet in eleven healthy adults over twenty-eight days. Urinary biotin and 3-hydroxyisovaleric acid were studied as early indicators, before obvious symptoms. This demonstrates research on functional biochemical changes under controlled conditions; it does not establish that a routine blood biotin measurement or consumer test can diagnose the cause of hair loss. The small experiment cannot estimate deficiency prevalence across all pregnancies or diets, nor establish a personal supplementation strategy. Deliberate depletion should not be reproduced outside research.[6]
Early hair and nail evidence mostly involved clinical cases
Patel and colleagues’ 2017 review identified eighteen reported cases involving hair or nail changes. The patients had underlying pathology, and reported improvement followed biotin use. Such case reports can suggest a question for further study, but cannot reliably separate treatment effects from natural change, concurrent care or selective reporting. They do not establish improved hair growth in otherwise healthy, biotin-replete people. Hair loss has several causes; a vitamin’s presence in commercial beauty products is not evidence that deficiency explains a particular person’s symptoms.[7]
A newer review retains uncertainty about routine supplementation
The 2026 alopecia review found no persuasive support for routine biotin use without documented deficiency. Its conclusions also distinguish biotin alone from combined regimens, where attribution is difficult. Differences in conditions, measurements and study design complicate inference. Absence of persuasive evidence is not proof that every possible population has no effect. It does mean that marketed promises need evidence beyond plausible metabolism and uncontrolled improvement. Clinically suspected deficiency or malabsorption is a different question from supplementing everyone with hair concerns.[8]
A large disease trial did not confirm an earlier promise
The 2020 SPI2 phase-three trial randomized 642 adults with progressive multiple sclerosis to pharmaceutical high-dose biotin or placebo. The primary improvement outcome at twelve months, confirmed at fifteen months, occurred in 12% versus 9%; its confidence interval included no clear difference. Disability or walking-speed benefit was not established. The authors did not recommend this treatment for progressive multiple sclerosis. A vitamin’s biochemical role or an earlier promising study does not outweigh a larger negative trial. These findings concern that disease-specific exposure, not correction of nutritional deficiency.[9]
No established upper limit does not certify unlimited safety
The 1998 US report could not set a biotin upper limit because available safety data were insufficient. That limitation is not a declaration that arbitrarily high exposure is harmless. Nutritional reference intake, clinical treatment of an inherited disorder and high-dose disease experiments have different purposes. The later laboratory-interference warning adds a clinically important issue beyond nutritional toxicity.[3]
Testing and nutritional inference remain limited
EFSA found insufficient biomarker evidence to determine biotin requirements. Controlled depletion research and inherited-disorder testing answer specialized questions. They should not be collapsed into a single consumer diagnosis of low biotin. A clinical assessment should consider the relevant symptoms, exposures and alternative causes before interpreting a test or considering targeted treatment.[2]
References
- Biotin: Health Professional Fact Sheet
Agency condition or prevention explanation
NIH Office of Dietary Supplements · Content/publication date: 2022
Accessed: 2026-10-14 UTC · Selected original official guidance or reference-report passages inspected on 2026-10-14 UTC; no independent clinical appraisal
Cited sections: 2022-01-10; Page update; vitamin and metabolic functions, brief foundation onlyExisting corpus attribution 159 words; this guide uses only its brief introduction, keeping cumulative attribution within 200. No consumer mirror used to extend allowance.
- Scientific Opinion on Dietary Reference Values for biotin
Reference intake report
EFSA NDA Panel · Content/publication date: 2014
Accessed: 2026-10-14 UTC · Original abstract and bibliographic record inspected on 2026-10-14 UTC; full text not independently appraised
Cited sections: 2014-02-24; Original abstract; functions, rare dietary deficiency, AI and biomarker limits - Dietary Reference Intakes: Chapter 11, Biotin
Reference intake report
Institute of Medicine / National Academies · Content/publication date: 1998
Accessed: 2026-10-14 UTC · Selected original official guidance or reference-report passages inspected on 2026-10-14 UTC; no independent clinical appraisal
Cited sections: 1998; Original chapter 11; free/bound forms, food sources, avidin, deficiency and insufficient UL dataURL chapter number 13 corresponds to printed chapter 11. NCBI version was challenged; original publisher chapter actually inspected. Only this URL receives attribution, and no counterpart is used to extend a budget.
- Biotinidase Deficiency
Clinical reference
Barry Wolf / GeneReviews · Content/publication date: 2026
Accessed: 2026-10-14 UTC · Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised
Cited sections: 2026-02-19; Last revision; original indexed diagnosis, newborn screening and management summaryOriginally posted March 24, 2000. Date verified by original indexed record turn2037search1/15. Direct chapter and PDF opening returned challenges. No disease-specific dose or administration recipe supplied.
- Biotin Interference with Troponin Lab Tests: Assays Subject to Biotin Interference
Agency condition or prevention explanation
US FDA · Content/publication date: not stated
Accessed: 2026-10-14 UTC · Selected original official guidance or reference-report passages inspected on 2026-10-14 UTC; no independent clinical appraisal
Cited sections: Undated; Current visible warning text; false troponin results and assay-specific mitigationNo publication/update date visible in inspected page; safety communications linked from it have their own dates. Existing corpus attribution 106 words; a short safety boundary is retained without duplicating the narrow assay guide.
- Indicators of marginal biotin deficiency and repletion in humans
Controlled depletion experiment
Mock and colleagues · Content/publication date: 2002
Accessed: 2026-10-14 UTC · Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised
Cited sections: 2002-11; Original indexed abstract and selected methods; eleven adults, twenty-eight days, urinary markersOriginal indexed conclusion inspected in turn2046search2 and original record turn2046search3/4. Direct PMC challenged; publisher direct opening failed. No general pregnancy prevalence inferred.
- A Review of the Use of Biotin for Hair Loss
Systematic review
Patel, Swink and Castelo-Soccio · Content/publication date: 2017
Accessed: 2026-10-14 UTC · Original abstract and bibliographic record inspected on 2026-10-14 UTC; full text not independently appraised
Cited sections: 2017-04-27; Original abstract; eighteen reported cases and healthy-population evidence limitPublisher first-online April 27, 2017 verified in turn2032search22; August 2017 issue. Case reports are not described as randomized evidence.
- Effectiveness of Biotin Supplementation for Hair Growth in Patients with Alopecia: A Systematic Review
Systematic review
Moltó-Balado and colleagues · Content/publication date: 2026
Accessed: 2026-10-14 UTC · Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised
Cited sections: 2026-05-04; Original indexed conclusions and selected discussion; routine use, combinations and attributionOriginal publisher opening initially exposed metadata but subsequent full text/find was incomplete. Date verified from publisher version notes turn2046search16. No study count copied from secondary reposts; selected original conclusions in turn2046search0/turn2048search13 support authored claims.
- Safety and efficacy of MD1003 in progressive multiple sclerosis (SPI2): phase 3 trial
Randomized controlled trial
Cree and colleagues · Content/publication date: 2020
Accessed: 2026-10-14 UTC · Original indexed abstract or selected original indexed passages inspected on 2026-10-14 UTC; direct opening attempted but incomplete, challenged or blocked; full text not independently appraised
Cited sections: 2020-12; Journal issue; original indexed abstract, 642 randomized, primary outcome and null interpretationOriginal methods/interpretation also inspected in turn2040search13, turn2048search0/1/3. PubMed incomplete and publisher forbidden. Dose omitted; pharmaceutical trial not equated with ordinary nutritional adequacy.
Scope & review
- Population
- General nutritional education; deficiency-risk contexts, inherited metabolic disease and progressive multiple sclerosis are distinguished
- Exposure or intervention
- Food biotin, targeted deficiency care, cosmetic supplements and pharmaceutical high-dose experiments
- Comparison
- Matched placebo in SPI2; uncontrolled cases and mixed interventions retain their limitations
- Outcomes
- Metabolic adequacy, specialized biomarkers, hair outcomes, disability, walking and test interference
- Timeframe
- 1998 and 2014 reference frameworks, 2002 depletion experiment, 2017/2026 reviews and 2020 trial
- Jurisdiction
- US/Canadian nutrient references, EU reference assessment, US FDA assay warning and original international research
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-14 UTC: Added cited nutrient functions, categories, outcome-specific evidence and uncertainty; qualified expert review remains pending.
What this article still leaves open
- Which hair-loss populations with confirmed deficiency benefit on objective outcomes?
- Which biomarkers have sufficiently validated clinical interpretation outside experimental depletion?
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.